Clarity Pharmaceuticals Ltd has released a press release.
Paediatric neuroblastoma trial advances to cohort 3
Filed with ASX ·
6ix hasn’t read this filing yet.
Clarity Pharmaceuticals Ltd. on 6ix
Earlier from Clarity Pharmaceuticals
- Imaging trial in prostate cancer opens for recruitment
- Application for quotation of securities - CU6
- Governance & Trading Policy Update
- IND Approval by US FDA for Phase II SAR-Bombesin trial
- Notification regarding unquoted securities - CU6
Later from Clarity Pharmaceuticals
- Recruitment opens for Phase II trial in Prostate Cancer
- First participants imaged in SAR-Bombesin trial
- First participant imaged in Phase II SAR-Bombesin trial
- First patient treated in therapeutic prostate cancer trial
- 50% recruitment milestone reached for prostate cancer trial
Follow Clarity Pharmaceuticals into a list and get an email when it puts out news.
Follow Clarity Pharmaceuticals